key: cord-0960506-dr4709qy
authors: Pérez‐Herrera, Lucia C.; Ordoñez‐Cerón, Sebastián; Moreno‐López, Sergio; Peñaranda, Daniel; García, Elizabeth; Peñaranda, Augusto
title: Impact of the COVID‐19 national lockdown in the allergic rhinitis symptoms in patients treated with immunotherapy at two allergy referral centers in Bogotá, Colombia
date: 2022-02-11
journal: Laryngoscope Investig Otolaryngol
DOI: 10.1002/lio2.738
sha: 03e0a1737203efef66ff600746ba1c106c12f86b
doc_id: 960506
cord_uid: dr4709qy

BACKGROUND: Coronavirus disease‐19 (COVID‐19) “lockdowns” caused an abruptly restricted access to health care services such as immunotherapy for allergic rhinitis (AR) and led to higher exposure to indoor allergens. This study aimed to assess the impact of COVID‐19 lockdowns on AR symptoms reported by the patients treated with immunotherapy who attended the Hospital Fundación Santa Fe de Bogotá and Unidad Médico Quirúrgica de Otorrinolaringología, Colombia. METHODS: Pre–post study that included patients with AR confirmed diagnosis (prick test), treated with immunotherapy before and after COVID‐19 lockdowns on March–June 2020. Visual analog scales (VAS) and sociodemographic questionnaires were applied to assess AR symptoms (nasal obstruction, pruritus, rhinorrhea, and ocular symptoms) and their associated factors. RESULTS: A total of 318 participants were included, and their mean age was 18.9 years (SD: 12.8). The median number of immunotherapy doses applied before isolation was 11 (interquartile range [IQR]: 6–19), and the median number of immunotherapy doses missed during isolation was three doses (IQR: 2–3). Up to 38.4% of the AR patients reported that their symptoms got worse during lockdowns. A pre–post mean difference in the VAS score of 0.5 was found for nasal obstruction (p = .01), 0.7 for pruritus (p < .001), 0.7 points for rhinorrhea (p < .001), and 0.8 for ocular symptoms (p < .001). Factors associated with worsening of AR symptom scores were pet ownership, atopic dermatitis, lower educational level, and a low number of immunotherapy doses applied before lockdowns. CONCLUSION: A large proportion of patients reported worsening of their AR symptoms, probably due to higher exposure to indoor AR allergens and interruption of immunotherapy during COVID‐19 lockdowns.

Conclusion: A large proportion of patients reported worsening of their AR symptoms, probably due to higher exposure to indoor AR allergens and interruption of immunotherapy during COVID-19 lockdowns.

allergic rhinitis, COVID-19, immunotherapy, lockdown, SARS-CoV2

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has significantly disrupted Latin American health care systems. 1, 2 Latin America is one of the regions with the highest rates of cases and mortality from coronavirus disease-19 . 3 Efforts to contain the spread of COVID-19 included isolation, movement restrictions, and national lockdowns, defined as large-scale physical distancing measures. 4 In Colombia, the first COVID-19 national lockdown was established between March and May 2020. Although lockdown restrictions were necessary to fight the pandemic, statistical models suggest that these restrictive measures mainly impacted patients with chronic diseases in low-and middle-income countries. 5, 6 Thus, in patients with chronic diseases such as allergic rhinitis (AR) or asthma, lockdowns could lead to higher exposure to indoor allergens and the interruption of their specific allergen immunotherapy. 7 Avoidance of indoor and outdoor allergens is considered the most effective primary preventive measure in patients with respiratory allergies. 8 Prior authors suggested a probable reduction of exposure to nasal irritants (i.e., pollen) in allergic populations located in polluted industrialized urban areas related to COVID-19 lockdowns. 9 However, the patients with AR could have a higher exposure to indoor allergens, such as dust mites or pet hair, and pollutants linked to human activities (i.e., tobacco, cooking smoke). 7, 9, 10 On the other hand, allergenspecific immunotherapy (SIT) is the only known treatment that changes the natural history of AR increasing patients' tolerance to allergen exposure and allowing a reduction in the pharmacological treatments. 11, 12 In some countries, patients undergoing immunotherapy were forced to stop this treatment due to restrictions on nonessential health care. 7 Indeed, in tropical low-/middle-income countries like Colombia, immunotherapy was interrupted during a brief period, and a higher indoors allergen exposure to house dust mites (HDM) and pets could lead to worsening of AR symptoms in these patients.

Prior studies describe a high prevalence of allergic diseases in tropical countries due to geographical and environmental characteristics that prompt the existence of specific allergens. 13 Among the most frequent allergens in tropical countries are HDM (Blomia tropicalis, Dermatophagoides pteronyssinus, and Dermatophagoides farinae), pet allergens (dog, cat, and others), and pollen (Gramineae, Cypress, etc.). 14 

The inclusion criteria were as follows: (a) patients aged 4-67 with a clinical diagnosis of AR performed by allergists and confirmed with skin prick test (SPT), (b) all the patients were treated with monthly depot allergen-SIT injections for at least 6 months which is considered as the maintenance phase for this type of SIT (the maintenance dose is reached the first day of immunotherapy), [15] [16] [17] [18] and (c) these patients attended the allergy referral centers between March and May 2020.

The exclusion criteria for this study were patients with severe systemic diseases and patients with any physical or mental disability that could limit the understanding of the questionnaires. The study population is located in Colombia, a low-/middle-income tropical country in Latin America. In the FSFB and UNIMEQ-ORL, patients are treated with monthly injections of pet-SIT, Gramineae-SIT, and two types of HDM-SIT: HDM duo that includes D. pteronyssinus and D. farinae allergen extracts (50%/50%), and HDM trio that includes B. tropicalis, D. pteronyssinus, and D. farinae (34%/33%/33%). These SIT extracts are an aluminum hydroxide-adsorbed depot allergen preparation produced by modification of the allergen by glutaraldehyde (glutaraldehyde polymerized). These characteristics preserve their capacity to be recognized by specific IgG and allow the administration of higher doses in a short period. 17, 18 Due to this safety profile, this type of SIT can be administered using a rush schedule, reaching the maintenance dose on the 1st day of immunotherapy. [15] [16] [17] [18] The treatment was performed with a rush-up dosing schedule with one injection of 0.5 ml per month, which is presented in a single vial at a concentration of 10,000 TU/ml.

Visual analog scales (VAS) scored from 0 (no symptoms) to 10 (severe symptoms) were applied to assess AR symptoms (nasal obstruction, pruritus, rhinorrhea, and ocular symptoms). VAS scores have outstanding reliability, good validity, moderate distribution-based responsiveness, and good anchor-based responsiveness compared to multi-item questionnaires. 19 Moreover, VAS scores are widely validated tools for the measurement of AR symptoms because they correlate well with the AR and its impact on asthma severity classification and with multi-item sino-nasal symptom scales such as the Sino-Nasal Outcome Test (SNOT-22). 20 disease severity, monitoring the course of the disease, and for treatment decisions and disease burden. 20, 21 VAS scores are applied on every SIT visit at our allergy centers as a follow-up tool to assess the course of the disease. The sociodemographic and clinical questionnaires including self-reported changes in AR symptoms were collected by trained researchers after the COVID-19 lockdown.

Statistical analysis was performed using Stata 16MP software. About the descriptive analysis, absolute and relative frequencies were calculated for the qualitative variables. Measures of central tendency (average and median) were estimated for the quantitative variables. Standard deviation and interquartile range were assessed for the dispersion measures. A "change from baseline" measure of the VAS score was calculated using the differences between the baseline VAS score obtained before the lockdown and the VAS score after the lockdown. A bivariate and multivariable analysis between pre-and postmeasurement data of the symptom's VAS scores was analyzed by the paired samples Wilcoxon test. A robust cluster linear regression was carried out to assess the effect of lockdowns in the VAS score for each symptom: nasal obstruction, pruritus, ocular symptoms, and rhinorrhea. This effect was adjusted considering the clinical and demographic variables with clinical relevance or biological plausibility and those with a p value ≤ 0.2 in a Pearson/Spearman test or analysis of variance/Friedman test. Model assumptions were validated through a linearity test, an estimation of standardized residuals and leverage values, and a comparison between the crude and the adjusted models. Hypothesis testing to determine the level of statistical significance was performed using a 95% confidence interval and a p value < .05.

A total of 318 individuals were included, with a mean age of 18.9 years (SD: 12.8), 55.1% (n = 211) were female, and 34.6% were aged over 18 years old. The baseline demographic and clinical characteristics of the study population are shown in Table 1 . Up to 38.4% (n = 122) reported a family history of rhinitis, 11.3% (n = 36) of atopic dermatitis, and 9.8% (n = 31) of asthma. Overall, 38.4% (n = 122) of the participants reported that their symptoms got worse during the lockdown period. The percentage of missing data was 13%, but considering that this percentage was lower than 20%, the authors did not perform any statistical imputation of data.

F I G U R E 1 Changes in AR symptoms during the lockdown period reported by the patients. AR = Allergic rhinitis 3.1 | SPT, pharmacotherapy, and immunotherapy results

The median number of immunotherapy doses applied before isolation was 11 (interquartile range [IQR]: [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , and the median number of immunotherapy doses missed during isolation was 3 (IQR: 2-3). 3.2 | Changes in AR symptoms and associated factors during lockdown Figure 1 shows the changes in AR symptoms reported by the patients during the lockdown. The median of the VAS scores before and after lockdown for nasal obstruction, pruritus, rhinorrhea, and ocular symptoms are shown in Figure 2 . The mean differences of these scores were 0.5 (SD: 2.9), 0.7 (SD: 3.1), 0.7 (SD: 2.8), and 0.8 (SD: 3.1), respectively. These changes in the scores were statistically significant. and our findings support the hypothesis of a higher indoor exposure that could lead to worsening of allergy symptoms during lockdowns.

However, considering that SARS-CoV-2 could cause similar symptoms to AR, patients could be more focused on these symptoms during this time and thus be more likely to report them. Besides, because patients were aware they were not getting their SIT shots, they might be more likely to perceive AR symptoms as more significant. All these factors should be considered for the interpretation of the results.

Regarding HDM sensitization in our population, the frequency of B. tropicalis sensitization was 52.2%, and this is a particularly important allergen in tropical countries. Prior studies in Mexico and Brazil described a frequency of B. tropicalis sensitization ranging from 12.1%

to 52.7%, respectively, in atopic patients. 24, 25 The frequency of B. Tropicalis was high compared to previous reports of atopic populations from temperate climate environments in high-income countries. 13, 25 Earlier studies describe that mite species have geographical fluctuations depending on the humidity and proximity to the equatorial zone. 13 The diverse environmental conditions in Latin

American tropical countries could account for these differences. 26 Furthermore, regarding pet allergens, our study showed a positive 21 Moreover, there is extensive data on the clinically significant magnitude of these changes in the VAS scores for AR, and VAS have also been successfully used in real-life and observational studies. 21 Therefore, these statistically significant differences found in our study are also clinically significant.

Moreover, the allergists of this study reviewed and classified all the information about pharmacotherapy and immunotherapy.

Regarding the limitations of the study, we highlight that the intensity of symptoms was assessed through self-reported questionnaires, and no objective tests were performed. Self-reported data can be strongly affected by reporter bias and overestimation of the true frequencies of the symptoms. 30 Moreover, reporter biases could be significant in a study of this type. About the environmental control measures in this study, we highlight that the allergists at both allergy centers provide education on allergen avoidance to all the patients with AR (i.e., avoidance of pets in the bedroom, rugs, and curtains, adequate ventilation of bedrooms). Attaching to the International Study of Asthma and Allergies in Childhood methodology, we obtained information about the floor material in the house because this is an important variable in allergic disease studies, 31 but no statistical association was found between AR symptoms and this variable. However, no additional environmental controls were applied in the study population which might have a significant effect on AR symptoms, and this is an important limitation of the study. Regarding pharmacotherapy, we stand out that this information was quite heterogenous for the study group. Despite specific doses of medications were prescribed by the allergists, we have no specific information about the changes in the pharmacotherapy, and there was not a standardized follow-up of changes in the doses of medications during this period. Moreover, pharmacotherapy was not correlated with the immunotherapy doses, and this variable can be a major factor in symptom scoring too. These issues should be considered as limitations of this study, and the results should be interpreted considering this scenario.

A large proportion of patients reported worsening of their AR symptoms, probably due to higher exposure to indoor allergens (i.e., HDM and pets) and immunotherapy discontinuation during the COVID-19

lockdowns. Although this study was carried out in an extraordinary context, it stands out the importance of long-term management, primary prevention, and control of AR by allergen avoidance measures, pharmacotherapy, and allergen-SIT. Environmental factors appeared to play a critical role in the pathogenesis of AR, and immunotherapy remains the only treatment that changes the natural history of this disease.

Latin American healthcare systems in times of pandemic

Effect of the COVID-19 pandemic on the mental health, daily and occupational activities of otolaryngologists and allergists in Colombia: a national study

Cross-sectional analysis of COVID-19 vaccine intention, perceptions and hesitancy across Latin America and the Caribbean

Barriers and coping mechanisms to accessing healthcare during the COVID-19 lockdown: a crosssectional survey among patients with chronic diseases in rural Rwanda

Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study

COVID-19 and its ramifications for cancer patients in low-resource settings: Ghana as a case study

COVID-19: when dust mites and lockdown create the perfect storm

Next-generation allergic rhinitis and its impact on asthma (ARIA) guidelines for allergic rhinitis based on grading of recommendations assessment, development and evaluation (GRADE) and real-world evidence

The impact of lockdown on allergic rhinitis: what is good and what is bad?

Stay at home': is it good or not for house dust mite sensitized children with respiratory allergies?

Impacto de la inmunoterapia subcutánea con Dermatophagoides farinae y Dermatophagoides pteronyssinus sobre la calidad de vida de pacientes con rinitis y asma alérgica

Specific immunotherapy in allergic rhinitis

Particularities of allergy in the tropics

Inmunoterapia con alérgenos: mecanismos de acci on, impacto terapéutico y socioecon omico. Consenso de la Asociaci on Colombiana de Alergias Asma e Inmunología

EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis

Comparison of allergen immunotherapy practice patterns in the United States and Europe

Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts

Determinaci on de la seguridad de la inmunoterapia subcutánea con extractos polimerizados de Dermatophagoides farinae, Dermatophagoides pteronyssinus y Blomia tropicalis administrada en pacientes con enfermedad alérgica

Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life?

Visual analogue scale for sino-nasal symptoms severity correlates with sino-nasal outcome test 22: paving the way for a simple outcome tool of CRS burden

Visual analogue scales (VAS): measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care

Life cycle and reproduction of house-dust mites: environmental factors influencing mite populations

COVID-19 lockdown and seasonal allergic rhinitis: our experience in 40 patients

Sensitization to Blomia tropicalis and Dermatophagoides pteronyssinus, farinae and siboney prevalence in patients with rhinitis, allergic asthma, or both, in a population of a metropolitan area of Mexico City

Medical, social, and environmental factors associated with allergic rhinitis and allergic rhinitis in comorbidity with asthma in children treated with immunotherapy in bogotá

Epidemiology of allergic rhinitis and associated risk factors in Asia

Frequency of self-reported allergies at a high-complexity referral hospital in Colombia, a tropical Latin American country

Information bias in health research: definition, pitfalls, and adjustment methods

The international study of asthma and allergies in childhood (ISAAC) phase three: a global synthesis

Impact of the COVID-19 national lockdown in the allergic rhinitis symptoms in patients treated with immunotherapy at two allergy referral centers in

The authors would like to thank all the nursing team at UNIMEQ-ORL who provided the technical support during the fieldwork. Moreover, the authors would like to thank the anonymous reviewers of this manuscript: Your feedback and thoughtful comments significantly improved our manuscript, thanks for supporting our work.

The authors declare no conflict of interest.

Lucia C. Pérez-Herrera https://orcid.org/0000-0001-8041-6433Augusto Peñaranda https://orcid.org/0000-0003-1598-8472